New peer-reviewed data in Practical Laboratory Medicine confirms the analytical reliability of Geneoscopy’s scrape-free collection method used in the FDA-approved ColoSense® colorectal cancer screening test.
Across more than 1,300 replicates, ColoSense showed high reproducibility under varied conditions — including different stool volumes, dietary interferences, freeze-thaw cycles, and transit times up to 120 hours. A prospective equivalency analysis demonstrated 94% agreement between in-lab FIT and traditional at-home FIT. Retrospective testing confirmed strong sensitivity for colorectal cancer and advanced adenomas.
Unlike traditional methods, ColoSense eliminates patient handling of stool and standardizes testing in the lab, reducing variability and improving patient experience. Geneoscopy will present its findings at ACG 2025 (Poster P2612, Oct. 27).